hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06356077, orgStudyIdInfo id: OBPM_HTN2024, briefTitle: Evaluation of the Satisfaction of a Hypertensive Population in Their Use of the Aktiia 24/7 Blood Pressure Monitor, acronym: OBPM_HTN2024, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Aktiia SA, class: INDUSTRY, descriptionModule briefSummary: OBPM_HTN2024 study was designed by AKTIIA SA to evaluate how a hypertensive population, reflective of the United States and encompassing a range of phenotypes, perceives the Aktiia 24/7 device (Aktiia G1) during their first 3 months of use., conditionsModule conditions: Hypertension, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 5000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Preferences of subjects regarding the method to monitor their blood pressure between Aktiia Bracelet, Home Blood Pressure Monitor, or Ambulatory Blood Pressure Monitor, primaryOutcomes measure: Frequency of Aktiia app use, primaryOutcomes measure: Frequency of use of Aktiia device as compared to previously use other blood pressure monitors, secondaryOutcomes measure: Evaluation of subject's experience in using the Aktiia App, secondaryOutcomes measure: Evaluation of the most valuable data on the Aktiia Mobile App by subjects, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06356064, orgStudyIdInfo id: E2-23-3834, briefTitle: Radial or Focus Extracorporeal Shock Wave Therapy in Epin Calcanei, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-15, primaryCompletionDateStruct date: 2023-12-15, completionDateStruct date: 2024-01-15, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: Objective: The aim of the study was to investigate the effectiveness of radial and focused ESWT treatment on pain, function, and size of the calcaneal spur in patients with a clinical and radiological diagnosis of epin calcanei.Methods: A total of 112 patients aged between 18 and 95 years were randomly divided into two groups: group 1 received rESWT (2.4 bar 12 hz 2000 beats), and group 2 received fESWT (0.14 bar 14 hz 1000 beats) three times a week for three weeks. All patients were evaluated using the Visual Analog Scale (VAS)-pain and Foot Function Index (FFI) before and after the treatment, at 4 weeks and 12 weeks. Epin size was measured radiographically in the patients before and after the treatment at the 12-week follow-up., conditionsModule conditions: Spur, Heel, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 112, type: ACTUAL, armsInterventionsModule interventions name: Extracorporeal shock wave therapy, outcomesModule primaryOutcomes measure: Visual Analog Scale, primaryOutcomes measure: Functional Foot Index, secondaryOutcomes measure: Radiographic assesment, epin size, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 95 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Özge TEZEN, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06356051, orgStudyIdInfo id: Gbuyukyilmaz, briefTitle: Cardiovascular Disease Risk in Children With Type 1 Diabetes Mellitus, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-06-01, completionDateStruct date: 2023-09-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: Epicardial fat thickness, carotid intima-media thickness, and augmentation index from arterial stiffness indicators are increased in children with T1DM compared to the healthy control group. These results support the idea that children with T1DM present significant changes in important subclinical indicators for the development of cardiovascular disease., conditionsModule conditions: Type 1 Diabetes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 202, type: ACTUAL, armsInterventionsModule interventions name: Echocardiography, outcomesModule primaryOutcomes measure: Epicardial fat thickness, secondaryOutcomes measure: carotid intima-media thickness, secondaryOutcomes measure: arterial stiffness parameters such as pulse wave velocity, augmentation index, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Ankara Bilkent City Hospital, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-01-04, uploadDate: 2024-03-30T05:04, filename: Prot_SAP_000.pdf, size: 347934, hasResults: False
protocolSection identificationModule nctId: NCT06356038, orgStudyIdInfo id: Prot. n. 76 SA/2022, briefTitle: Phrenic Nerve Infiltration: Pulmonary Expansion and Pain Control, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-03-09, primaryCompletionDateStruct date: 2025-01-02, completionDateStruct date: 2025-01-02, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Azienda Ospedaliera "Sant'Andrea", class: OTHER, descriptionModule briefSummary: Between January 2021-2023, 65 consecutive patients at risk for PAL (defined in accordance to "2019 Society of Thoracic Surgery score-criteria of PAL") underwent lung resection (lobectomy or sublobar resection) for malignancy. 5 patients were lost. The remaining have been assigned with a 1:2 randomization into: group A (22 patients), received intra-operative phrenic nerve infiltration with Ropivacaine 10 mg/ml in the peri-neurotic fat on the pericardium and group B (38 patients), did not receive infiltration. Data on hemidiaphragm elevation, air leaks, pain at 24 and 72 hours post-surgery, shoulder pain, length of hospital stay, length of chest tube permanence, were retrospectively collected and compared.The aim of the study is to investigate the effect of intra-operative phrenic nerve infiltration with long acting anesthetic in patients at high risk for PAL, improving pulmonary expansion after surgery, and reducing air leaks, while controlling post-operative pain., conditionsModule conditions: Prolonged Air Leak, conditions: Post-operative Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 66, type: ACTUAL, armsInterventionsModule interventions name: intra-operative phrenic nerve infiltration, outcomesModule primaryOutcomes measure: rate of pulmonary expansion due by phrenic nerve intra-operative local anaesthetic infiltration, secondaryOutcomes measure: rate of post-operative pain control after intra-operative phrenic nerve infiltration with local anaesthetic, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azienda Ospedaliera "Sant'Andrea", city: Roma, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06356025, orgStudyIdInfo id: 52082, secondaryIdInfos id: 2024-512546-42, type: EUDRACT_NUMBER, briefTitle: Botulinum Toxin Injection in the UES for R-CPD, acronym: BOTUS R-CPD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2027-07, completionDateStruct date: 2027-07, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: AZ Delta, class: OTHER, collaborators name: KU Leuven, descriptionModule briefSummary: The aim of this study is to assess the effect of botulinum toxin injection into the upper esophageal sphincter in a double blind, placebo controlled study. Investigators want to assess the effect on symptoms short term (1-20 weeks after BT injection), and long term (48 weeks after BT injection).This is a prospective double-blind randomized placebo-controlled study. Questionnaires assessing symptoms will be filled out on several occasions. At 20 weeks, a reassessment of symptoms will be done, without unblinding patients or investigator. Failures (to BT or placebo, defined as no clinical improvement or improvement less than 50%) will get the chance to receive a second procedure with active treatment (BT) in open label., conditionsModule conditions: Retrograde Cricopharyngeus Dysfunction, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: botulinum toxin type A, interventions name: Sodium Chloride 0.9% Inj, outcomesModule primaryOutcomes measure: Change of at least 50% of 'inability to belch' using the symptom questionnaire at week 12., secondaryOutcomes measure: Change in associated gastrointestinal symptoms: abdominal bloating/discomfort, secondaryOutcomes measure: Change in associated gastrointestinal symptoms: abdominal/chest pain, secondaryOutcomes measure: Change in associated gastrointestinal symptoms: flatulence, secondaryOutcomes measure: Change in associated gastrointestinal symptoms: gurgling noises from the chest/lower neck, secondaryOutcomes measure: Change of at least 50% of 'inability to belch' during long term follow-up at week 20, and at 48 weeks., secondaryOutcomes measure: Overall treatment effect (OTE), secondaryOutcomes measure: Overall symptom severity (OSS), secondaryOutcomes measure: EuroQol-5D (EQ-5D), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06356012, orgStudyIdInfo id: 71163523.1.0000.5437, briefTitle: Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Barretos Cancer Hospital, class: OTHER, collaborators name: Fundação de Amparo à Pesquisa do Estado de São Paulo, collaborators name: Farmoquimica S.A., collaborators name: Hospital de Cancer de Barretos - Fundacao Pio XII, descriptionModule briefSummary: The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients., conditionsModule conditions: HSIL, High-Grade Squamous Intraepithelial Lesions, conditions: Vaginal Microbiome, conditions: Biomarkers, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 96, type: ESTIMATED, armsInterventionsModule interventions name: Imiquimod, interventions name: Loop Electrosurgical Excision Procedure, outcomesModule primaryOutcomes measure: Number of participants with histological regression of High-grade squamous intraepithelial lesion (HSIL), secondaryOutcomes measure: Identification of immune response in vaginal and plasma collection, otherOutcomes measure: Correlation between vaginal microbiome and immunological response, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 45 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06355999, orgStudyIdInfo id: 2007p000646-F, briefTitle: Levari Exp.20: 2D - Partial Feedback, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-01, primaryCompletionDateStruct date: 2021-06-01, completionDateStruct date: 2021-06-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, descriptionModule briefSummary: Suppose that observers are trying to classify a spot on the skin as normal or abnormal and suppose that the two attributes that are important are the color and shape of the spot. The investigators have found that perceptual decisions of this short are shaped by the prevalence of the target abnormality and by the feedback that observers (Os) receive. If abnormal spots are rare (low prevalence), Os will tend to become more conservative about calling spots abnormal. In this experiment, Os see items defined by color and shape. They are looking for one combination (bumpy green). Bumpy green targets can be common (50% prevalence) or rare (10%). Os in one group will get feedback about their responses based on color. The other group will receive feedback based on shape. The investigators will look for effects of prevalence and of the type of feedback. The goal is to better understand perceptual decisions in settings like clinical evaluation of skin lesions., conditionsModule conditions: Form Perception, conditions: Color Perception, conditions: Decision Making, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two groups, each receiving different feedback, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Observers are naive as to the purpose of the experiment until after participation, whoMasked: PARTICIPANT, enrollmentInfo count: 55, type: ACTUAL, armsInterventionsModule interventions name: Feedback, outcomesModule primaryOutcomes measure: Participant naming of visual stimuli, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Visual Attention Lab / Brigham and Women's Hospital, city: Boston, state: Massachusetts, zip: 02215, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06355973, orgStudyIdInfo id: 2024-01-061, briefTitle: A Pilot Study for Efficacy of Cognitive and Physical Training in Patients With Mild Cognitive Impairment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: MinYoung Kim, MD, PhD, class: OTHER, descriptionModule briefSummary: This is to find out the effectiveness of cognitive and physical function training for patients with mild cognitive impairment.It is for the prevention and treatment of dementia in the future. randomized, Pilot Study., conditionsModule conditions: Patients With Mild Cognitive Impairment (MCI), designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Using tablets and workbooks cognitive function., interventions name: self-programming of physical function training., outcomesModule primaryOutcomes measure: Montreal Cognitive Assessment (MoCA), secondaryOutcomes measure: Korean-Mini Mental Status Examination (K-MMSE), secondaryOutcomes measure: Clinical Dementia Rating (CDR), secondaryOutcomes measure: Clinical Global Impressions of Change (CGIC), secondaryOutcomes measure: Instrumental Activities of Daily Living (I-ADL), secondaryOutcomes measure: Berg Balance Scale (BBS), secondaryOutcomes measure: Geriatric Quality of Life-Dementia (GQOL-D), secondaryOutcomes measure: Geriatric Depression Scale (GDSd), secondaryOutcomes measure: Global Deterioration Scale (GDS), secondaryOutcomes measure: Electroencephalography, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06355960, orgStudyIdInfo id: 2024-853, briefTitle: Effect of Dexmedetomidine on Oxygenation and Lung Mechanics, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Dexmedetomidine is a selective α -2 agonist widely used in anesthesia for its sympatholytic, sedative and analgesic effects . Favorable respiratory effects in animals, and in selected human patient groups have been reported when using this agent .we investigated the effects of different doses of dexmedetomidine infusion on oxygenation, conditionsModule conditions: Drug Use, conditions: Dexmedetomidine, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 176, type: ESTIMATED, armsInterventionsModule interventions name: GROUP Dexmedetomidine, interventions name: GROUP B, interventions name: GROUP C, outcomesModule primaryOutcomes measure: Oxygenation by the end study, secondaryOutcomes measure: Intraoperative dynamic lung compliance, secondaryOutcomes measure: Intraoperative static lung compliance, secondaryOutcomes measure: Physiological dead space, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cairo university, city: Cairo, zip: 11562, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06355921, orgStudyIdInfo id: RFAdesmoid, briefTitle: A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors, acronym: RFAdesmoid, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-02-01, completionDateStruct date: 2028-05-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Blokhin's Russian Cancer Research Center, class: OTHER, descriptionModule briefSummary: This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors.In the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated using MRI and CT studies and, if solid components of the tumor are detected, repeated surgical treatment is performed followed by active monitoring after 1 month.In the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months., conditionsModule conditions: Desmoid Tumor, conditions: Desmoid Fibromatosis, conditions: Desmoid, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 27, type: ESTIMATED, armsInterventionsModule interventions name: radiofrequency ablation, outcomesModule primaryOutcomes measure: Comparison of safety assessment., secondaryOutcomes measure: Overall Response Rate, secondaryOutcomes measure: Duration of responce, secondaryOutcomes measure: Comparison of tumor necrosis based on MRI/CT, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), city: Moscow, state: MO, zip: 115522, country: Russian Federation, contacts name: Artem Galustov, role: CONTACT, phone: 9169117818, email: artem115583@mail.ru, contacts name: Aslan Valiev, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Denis Sofronov, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 55.75222, lon: 37.61556, hasResults: False
protocolSection identificationModule nctId: NCT06355908, orgStudyIdInfo id: TT002, briefTitle: IL13Rα2 CAR-T for Patients With r/r Glioma, acronym: ENHANCING, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-21, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2027-05-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Yang Zhang, class: OTHER, collaborators name: TCRCure Biopharma Ltd., descriptionModule briefSummary: This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma., conditionsModule conditions: Glioma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: IL13Rα2 CAR-T, outcomesModule primaryOutcomes measure: Safety of IL13Rα2 CAR-T, secondaryOutcomes measure: Overall Response Rate (ORR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Progression Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Overall Survival (OS) at 6 months (OS6), secondaryOutcomes measure: Overall Survival (OS) at 12 months (OS12), secondaryOutcomes measure: The levels of IL13Rα2 CAR-T cell and IL13Rα2 CAR in the CSF and peripheral blood, secondaryOutcomes measure: The levels of cytokines in the CSF and peripheral blood, otherOutcomes measure: The Exploratory Indicators, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Tiantan Hospital, status: RECRUITING, city: Beijing, country: China, contacts name: Yang Zhang, MD, phD, role: CONTACT, phone: +861059976516, email: zhangyang8025@yeah.net, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False